EP2099772A2 - Hydrates de chlorhydrate d'erlotinibe - Google Patents

Hydrates de chlorhydrate d'erlotinibe

Info

Publication number
EP2099772A2
EP2099772A2 EP07819481A EP07819481A EP2099772A2 EP 2099772 A2 EP2099772 A2 EP 2099772A2 EP 07819481 A EP07819481 A EP 07819481A EP 07819481 A EP07819481 A EP 07819481A EP 2099772 A2 EP2099772 A2 EP 2099772A2
Authority
EP
European Patent Office
Prior art keywords
erlotinib hydrochloride
hydrate
hemihydrate
crystalline
erlotinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07819481A
Other languages
German (de)
English (en)
Inventor
Raymond Jozef Hubertus Westheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP2099772A2 publication Critical patent/EP2099772A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to novel hydrates of erlotinib hydrochloride, a process for preparing them, pharmaceutical compositions thereof and their use as a medicament.
  • Erlotinib is a compound that inhibits the human epidermal growth factor receptor tyrosine kinase, also known as EGFR-TK, that is critical for growth of malignant cells. EGFR over expression is associated with disease progression, and reduced survival. Erlotinib acts by blocking tyrosine kinase activity of EGFR-TK, resulting in inhibition of signaling pathway, and decreased growth of malignant tumors. Erlotinib is thus useful for the treatment of proliferative disorders such as cancers in humans. Erlotinib is marketed as its hydrochloride salt.
  • WO 96/30347 discloses the preparation of erlotinib hydrochloride in example 20, by reaction of the base in chloroform/ether mixture with IN HCl. It is only mentioned that it has a melting point of 228-23O 0 C.
  • European patent application EP 1044969 discloses processes for the synthesis of erlotinib hydrochloride (examples 4, 7 and 9-11). In these processes, alcoholic solvents propan-2-ol, butan-1-ol, butan-2-ol and 2-methoxyethanol were used for the precipitation of the erlotinib hydrochloride by concentrated HCl. No data concerning the crystalline form of the hydrochloride compounds are disclosed except a melting point in example 4 of 226-229 0 C.
  • WO 01/34574 disclosed the existence of two polymorphic Forms of erlotinib hydrochloride which were designated as Form A and B. Form B is thermodynamically more stable than Form A.
  • WO 2004/072049 disclosed the existence of another polymorph of erlotinib hydrochloride, designated as Form E, which showed similar stability as Form B but with a higher solubility. It may be prepared by precipitation of erlotinib hydrochloride from trifluorotoluene.
  • the polymorphs disclosed above are anhydrous compounds, i.e. they do not comprise water in the crystalline lattice.
  • the present invention relates to the discovery of hydrates of erlotinib hydrochloride.
  • Such compounds can be used as an alternative for the anhydrous erlotinib hydrochlorides in the treatment of proliferative disorders.
  • the compounds of the invention have the advantage that they can be prepared by crystallization from an aqueous solution without use of an organic solvent, providing possible purification and ecological benefits.
  • one aspect of the present invention relates to crystalline erlotinib hydrochloride hydrates.
  • the hydrate is a hemihydrate such as hemihydrate Form I, which can be characterized by, inter alia, an XRPD pattern having the following XRPD peaks at 20: 5.8, 9.4, 10.0, 11.1, 11.6, 17.5, 18.6, 24.9, and 26.8 +/- 0.2 degrees or hemihydrate Form II which can be characterized by, inter alia, an XRPD pattern having the following XRPD peaks at 20: 5.8, 10.6, 12.1, 14.6, 15.1, 17.3, 19.3, 24.3, 26.3, +/- 0.2 degrees.
  • a second aspect of the present invention relates to a process for the preparation of a hydrate of erlotinib hydrochloride comprising crystallizing erlotinib hydrochloride hydrate from an aqueous solution of erlotinib hydrochloride, preferably in the absence of organic solvent, and typically at a temperature of 20°C of less.
  • the process is used to make a hemihydrate such as Form I or Form II.
  • a third aspect of the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a crystalline erlotinib hydrochloride hydrate and a pharmaceutically acceptable excipient.
  • the hydrate is a hemihydrate, such as Form I or Form II.
  • the crystalline erlotinib hydrochloride hydrate is contained in a pharmaceutically effective amount and is frequently in a solid dosage form such as a tablet or capsule.
  • a fourth aspect of the invention relates to the use of an erlotinib hydrochloride hydrate and their pharmaceutical compositions as a medicament.
  • the use is for the treatment of cancer wherein the cancer is from the group of brain, squamous cell, bladder, gastric, pancreatic, hepatic, glioblastoma multiform, head, neck, esophageal, prostate, colorectal, lung, renal, kidney, ovarian, gynecological, thyroid, non- small cell lung (NSCLC), refractory, ovarian, or head and neck cancer.
  • NSCLC non- small cell lung
  • a fifth aspect relates to the use of the erlotinib hydrochloride hydrates for making anhydrous erlotinib hydrochloride.
  • Scan step time between 1-6 seconds
  • the FT-IR experiments were performed according to the KBr-method.
  • the FT-IR spectra were recorded from 600 cm “1 to 4000 cm “1 . From each FT-IR spectrum a blank FT-IR spectrum of KBr was subtracted. That blank IR spectrum was recorded prior to the measurements of the samples.
  • a hydrate is a compound that contains water bound thereto. Hydrates are normally qualified by their degree of hydration, i.e. the molar amount of water bound to a molecule. A monohydrate typically has a degree of hydration of 0.9 to 1.05 molar equivalents of water per mol of erlotinib. A hemihydrate typically has a degree of hydration between 0.45 and 0.55 molar equivalents of water. While the hydrate compounds of the present invention are not limited to any particular degree of hydration, the hemihydrate compound is generally preferred.
  • Two preferred hemihydrates are: erlotinib hydrochloride hemihydrate Form I which can be characterized by XRPD peaks at 2 ⁇ of 5.8, 9.4, 10.0, 1 1.1, 11.6, 17.5, 18.6, 24.9, and 26.8 +/- 0.2 degrees, or FT-IR peaks at 900, 950, 1152, 1216, 1484, 3254, 3327, and 3382 +/- 4 cm "1 , and erlotinib hydrochloride hemihydrate Form II which can be characterized by XRPD peaks at 2 ⁇ of 5.8, 10.6, 12.1, 14.6, 15.1, 17.3, 19.3, 24.3, and 26.3, +/- 0.2 degrees or FT-IR peaks at 649, 867, 901, 948, 1029, 1073, 1213, 1242, 1355, 1431, 1484, 1624, and 3401 +/- 4 cm "1 .
  • the crystalline hemihydrate Forms I and II can normally be identified by either the XRPD peaks or FT-IR peaks, and in practical terms will typically exhibit both.
  • the peaks are not exhaustive.
  • relatively pure Form I will generally exhibit the following XRPD peaks: 5.8, 6.3, 9.4, 10.0, 11.1, 11.6, 12.5, 13.4, 14.4, 14.8, 15.1, 16.4, 17.5, 18.1, 18.6, 20.1, 20.4, 20.7, 21.4, 22.1, 23.0, 23.3, 24.0, 24.3, 24.9, 25.3, 26.8, 27.9, 28.5, 28.8, 29.3, 29.8, 30.3, 33.1 +/- 0.2 degrees and/or the following FT-IR peaks: 628, 649, 685, 783, 852, 861, 887, 894, 900, 941, 950, 975, 1029, 1048, 1075, 1096, 1132, 1 152, 1170, 1198, 1216, 1243, 1288, 1323, 1335, 1354
  • Form I in relatively pure state will exhibit an XRPD pattern that substantially corresponds to Fig. 1 and an FT-IR that substantially corresponds to Fig. 3.
  • Form II will exhibit an XRPD and/or FT-IR that substantially corresponds to Figs. 4 and 6, respectively.
  • the erlotinib hydrochloride hydrates of the present invention can be prepared by forming an aqueous solution of erlotinib hydrochloride in water, such as by dissolving the salt therein or forming it in situ, followed by crystallization of an erlotinib hydrochloride hydrate.
  • the Form which may be obtained depends among others on the concentration of erlotinib hydrochloride in water, the crystallization temperature, the crystallization time and if stirring is applied during crystallization. Generally it is preferred that the aqueous solution does not contain an organic solvent, though minor ( ⁇ 40%) or trace amounts ( ⁇ 2%) can be present.
  • the temperature is typically low, such as 2O 0 C or less and generally 10 0 C or less. Stirring is usually avoided, at least on small scale. Seeding crystals may also be used during the precipitation.
  • a concentration of about 1% of erlotinib hydrochloride by weight in water can be used as the aqueous solution and crystallization can be performed at about 4 0 C for 28 days without stirring.
  • the erlotinib hydrochloride hydrates may also be prepared by contacting erlotinib base with aqueous hydrochloric acid in an aqueous environment. Erlotinib free base may be dissolved in an aqueous hydrochloride solution to form the erlotinib hydrochloride solution in situ. The erlotinib hydrochloride hydrate may be crystallized from this solution as described above. Generally 1 to 1.5 equivalents of HCl is used. [0033] The solubility of hydrated forms is usually less than the solubility of anhydrous forms. This reduced solubility may be used as an advantage for the purification of the compounds.
  • the hydrated Forms may lose their bonded water by heating, by placing the compound under vacuum, or by recrystallizing under removal of water with, for instance, a Dean Stark trap to form a non-hydrated erlotinib hydrochloride Form.
  • any of the prior art Forms e.g., Form A, Form B, or Form E may be obtained.
  • the crystalline erlotinib hydrochloride hydrate of the present invention is formed as described above and converted to the desired erlotinib compound.
  • the hydrate as a starting material to re-crystallize erlotinib hydrochloride as Form A, Form B, or Form E, different impurities may be removed by the two crystallizations being carried out under different solvent and crystallization conditions.
  • the recrystallization is carried out in a non-aqueous solvent system, i.e., consisting or comprising an organic solvent especially an alcoholic solvent or trifluorotoluene, although water can also be present as described above.
  • a non-aqueous solvent system i.e., consisting or comprising an organic solvent especially an alcoholic solvent or trifluorotoluene, although water can also be present as described above.
  • the crystallization conditions as described in the prior art for the preparation of these specific Form A, Form B or Form E are used.
  • the invention also relates to the use of erlotinib hydrochloride hydrates and their pharmaceutical compositions as a medicament.
  • the use is for the treatment of cancer wherein the cancer is from the group of brain, squamous cell, bladder, gastric, pancreatic, hepatic, glioblastoma multiform, head, neck, esophageal, prostate, colorectal, lung, renal, kidney, ovarian, gynecological, thyroid, non-small cell lung (NSCLC), refractory, ovarian, or head and neck cancer.
  • the pharmaceutical composition can be in the form of enteral, parenteral or transdermal administration.
  • the composition can be administered orally in the form of tablets, capsules, solutions, suspensions or emulsions.
  • the composition can also be administered in the form of an injection solution or suspension or infusion solution, or transdermally with for instance a patch.
  • Pharmaceutical compositions can be obtained in a way which is common for a person skilled in the art.
  • compositions comprise a hydrate compound of the invention, or a mixture of compounds thereof, typically in a therapeutically effective amount, and a pharmaceutically acceptable excipient.
  • Suitable dosage regimens comprise from 0.001 to 100 mg/kg/day.
  • Suitable excipients include solid inert diluents or fillers such as for example lactose, starches, calcium hydrogen phosphate etc., or liquids such as water, alcohols, paraffin's glycerol or polyols etc, and waxes etc. which will be apparent for the skilled persons in the art of preparing pharmaceutical compositions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention porte sur un hydrate de chlorhydrate d'erlotinibe cristallin et sur un procédé de fabrication d'un anhydrate d'erlotinibe cristallin, qui comprend la cristallisation d'un hydrate de chlorhydrate d'erlotinibe à partir d'une solution aqueuse de chlorhydrate d'erlotinibe; et la recristallisation dudit hydrate de chlorhydrate d'erlotinibe à partir d'un système solvant non aqueux afin de créer un chlorhydrate d'erlotinibe anhydre de forme A, de forme B ou de forme E.
EP07819481A 2006-10-27 2007-10-26 Hydrates de chlorhydrate d'erlotinibe Withdrawn EP2099772A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86315806P 2006-10-27 2006-10-27
PCT/EP2007/009447 WO2008049645A2 (fr) 2006-10-27 2007-10-26 Hydrates de chlorhydrate d'erlotinibe

Publications (1)

Publication Number Publication Date
EP2099772A2 true EP2099772A2 (fr) 2009-09-16

Family

ID=39251354

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07819481A Withdrawn EP2099772A2 (fr) 2006-10-27 2007-10-26 Hydrates de chlorhydrate d'erlotinibe

Country Status (5)

Country Link
US (1) US8372856B2 (fr)
EP (1) EP2099772A2 (fr)
AR (1) AR063415A1 (fr)
CL (1) CL2007003089A1 (fr)
WO (1) WO2008049645A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2162444B1 (fr) * 2007-07-11 2014-06-04 Hetero Drugs Limited Procédé amélioré de préparation de l'hydrochlorate d'erlotinibe
EP2213665A1 (fr) * 2007-08-17 2010-08-04 Hetero Drugs Limited Chlorhydrate d'erlotinib
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
AU2011298167B2 (en) 2010-07-23 2015-11-26 Generics [Uk] Limited Pure erlotinib
CN103570634B (zh) * 2012-08-10 2018-01-26 上海创诺医药集团有限公司 盐酸埃罗替尼多晶型物及其制备方法
WO2014023027A1 (fr) * 2012-08-10 2014-02-13 上海创诺医药集团有限公司 Polymorphe de chlorhydrate d'erlotinib et son procédé de préparation
US9593083B2 (en) * 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
WO2014118737A1 (fr) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Sels d'erlotinib
CN106749048B (zh) * 2017-01-14 2020-03-20 山东裕欣药业有限公司 一种盐酸厄洛替尼晶型化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3103799B1 (fr) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Derives de quinazoline
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008049645A2 *

Also Published As

Publication number Publication date
CL2007003089A1 (es) 2008-05-09
WO2008049645A2 (fr) 2008-05-02
US20080167327A1 (en) 2008-07-10
WO2008049645A3 (fr) 2008-07-31
US8372856B2 (en) 2013-02-12
AR063415A1 (es) 2009-01-28

Similar Documents

Publication Publication Date Title
US8372856B2 (en) Hydrates of erlotinib hydrochloride
US7928114B2 (en) Crystalline erlotinib
US8703967B2 (en) Crystal form of sunitinib malate
CA2821102C (fr) Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
KR102142796B1 (ko) 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도
IL178097A (en) Polymorphs of IMATINIB acid addition salts with tensulfonic acid
US10550101B2 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
WO2011033307A1 (fr) Sel de dichlorhydrate de nilotinib
KR101579148B1 (ko) 4-페닐아미노 퀴나졸린 유도체의 다형체, 그 제조 방법 및 용도
WO2012090221A1 (fr) Nouveaux sels d'imatinib
JP7139116B2 (ja) フェニルアミノピリミジン化合物またはその塩の多形物
RU2680826C2 (ru) Новая соль 3-[(3-{ [4-(4-морфолинилметил)-1н-пиррол-2-ил]метилен} -2-оксо-2,3-дигидро-1н-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона, ее получение и содержащие ее композиции
EP3397618B1 (fr) Procédé de fabrication d'une forme cristalline a de géfitinib
US20070032506A1 (en) Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
US8471032B2 (en) Benzimidazole compound in crystal form and salt thereof
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
EP1844018A2 (fr) Formes cristallines du mésylate de fenoldopam
CN116075504A (zh) 化合物的结晶形式
WO2014136126A2 (fr) Procédé pour la préparation de forme a du chlorhydrate d'erlotinib

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090527

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20131211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150220